None listed
Conditions
Interventions
Drug : A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days
B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days
C: Pregabalin plus
Sponsors
Unimed Pharm
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Body weight ae least 50kg and BMI(body mass index) within the range of 18 to 27kg/m2 2) Provision of signed written informed consent 3) Acceptable physical examination and clinical examination, during screening
Exclusion criteria
Exclusion criteria: 1) A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease 2) A subject with a history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug 3) A subject with history of allergies including study drug (pregabalin or thioctic acid) or other drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies 4) A subject whose lab test results are as follows: AST(SGOT), ALT(SGPT) > 1.5 x upper limit of reference range 5) Presence or history of drug abuse or positive result in urine drug screening test 6) Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 14 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (if used medication is considered acceptable by investigator, patients can be included) 7) Participation in clinical trials of any drug within 60 days prior to the participation of the study 8) Blood donation during 2 months or apheresis during 1 month before the study 9) Use of alcohol over 21 units/weeks 10) Smoker who smoke more than 10 cigarettes per day or who cannot stop smoking during the study period (from 24 hours before hospitalization to discharge) 11) Use of caffeine drink during the study period(from 24 hours before hospitalization to discharge) 12) A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products during the study 13) Judged to be inappropriate for the study by the investigator after reviewing clinical laboratory results or other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCt,ss;Cmax | — |
Secondary
| Measure | Time frame |
|---|---|
| Ctrough,ss;Tmax,ss | — |
Countries
Korea, Republic of
Contacts
Public ContactLi Young Ahn
Seoul National University Hospital
Outcome results
None listed